Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Sees Much More In Sirtris Than Meets The Eye – IN VIVO Blog

This article was originally published in The Pink Sheet Daily

Executive Summary

How does an early-stage biotech company, focused on a single set of targets, with a lone compound in early Phase II and everything else preclinical (including its most promising compounds), command a buyout price of $720 million?

You may also be interested in...



BIO CEO & Investor Conference In Brief

CytRx looks to put arimoclomal on track: CytRx plans to submit a toxicology report to FDA in the second quarter to facilitate the return of its Phase II candidate arimoclomal for Amyotrophic Lateral Sclerosis to the clinic, VP-Business Development David Haen said during the BIO CEO & Investor Conference in New York Feb. 9-10. The drug was put on clinical hold by FDA in January 2008 due to toxicology concerns stemming from an earlier rat study. CytRx conducted another study to address FDA's concerns. Arimoclomal is one of the firm's key internal assets; the firm is seeking to partner the drug. "We have had this cloud, this clinical hold, but we do expect it to be resolved," Haen said

BIO CEO & Investor Conference In Brief

CytRx looks to put arimoclomal on track: CytRx plans to submit a toxicology report to FDA in the second quarter to facilitate the return of its Phase II candidate arimoclomal for Amyotrophic Lateral Sclerosis to the clinic, VP-Business Development David Haen said during the BIO CEO & Investor Conference in New York Feb. 9-10. The drug was put on clinical hold by FDA in January 2008 due to toxicology concerns stemming from an earlier rat study. CytRx conducted another study to address FDA's concerns. Arimoclomal is one of the firm's key internal assets; the firm is seeking to partner the drug. "We have had this cloud, this clinical hold, but we do expect it to be resolved," Haen said

2008 Deals Of The Year

Each week, "The Pink Sheet" presents commentary on some of the most interesting new business deals, contributed by the editors of the IN VIVO blog. As 2008 came to a close, the editors nominated the following transactions as their top deals of the year. Feeling moved to weigh in with your own favorite? 1Full write-ups of each deal and IVB's poll can be found at: http://invivoblog.blogspot.com/search/label/DOTY

Related Content

Topics

UsernamePublicRestriction

Register

PS067643

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel